Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(4-((2s,5s)-5-((4-chlorophenyl)methyl)-2-methylmorpholin-4-yl)piperidin-1-yl)-1h-1,2,4-triazol-5-amine
2. Oatd-01
1. Oatd-01
2. 2088453-21-6
3. Chembl4788866
4. 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine
5. 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-4h-1,2,4-triazol-3-amine
6. Unii-x4d0g881cn
7. Glpg4716
8. Schembl18577306
9. Schembl23143248
10. Gtpl11617
11. Ex-a5697
12. Bdbm50554340
13. Compound 9 [pmid: 33078933]
14. Hy-137464a
15. Cs-0146704
16. 3-[4-[(2s,5s)-5-[(4-chlorophenyl)methyl]-2-methylmorpholin-4-yl]piperidin-1-yl]-1h-1,2,4-triazol-5-amine
17. 5-[4-[(2~{s},5~{s})-5-[(4-chlorophenyl)methyl]-2-methyl-morpholin-4-yl]piperidin-1-yl]-1~{h}-1,2,4-triazol-3-amine
18. Qgb
| Molecular Weight | 390.9 g/mol |
|---|---|
| Molecular Formula | C19H27ClN6O |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 390.1934872 g/mol |
| Monoisotopic Mass | 390.1934872 g/mol |
| Topological Polar Surface Area | 83.3 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 469 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A OATD-01 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of OATD-01, including repackagers and relabelers. The FDA regulates OATD-01 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. OATD-01 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A OATD-01 supplier is an individual or a company that provides OATD-01 active pharmaceutical ingredient (API) or OATD-01 finished formulations upon request. The OATD-01 suppliers may include OATD-01 API manufacturers, exporters, distributors and traders.
OATD-01 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of OATD-01 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right OATD-01 GMP manufacturer or OATD-01 GMP API supplier for your needs.
A OATD-01 CoA (Certificate of Analysis) is a formal document that attests to OATD-01's compliance with OATD-01 specifications and serves as a tool for batch-level quality control.
OATD-01 CoA mostly includes findings from lab analyses of a specific batch. For each OATD-01 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
OATD-01 may be tested according to a variety of international standards, such as European Pharmacopoeia (OATD-01 EP), OATD-01 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (OATD-01 USP).
LOOKING FOR A SUPPLIER?
